- At 36 weeks, Taltz and Zepbound met primary and secondary endpoints in the TOGETHER-PsO Phase 3b trial.
- 27.1% of patients achieved complete skin clearance and ≥10% weight loss with Taltz and Zepbound.
- Patients on Taltz and Zepbound were 40% more likely to achieve PASI 100 than those on Taltz alone.
Study Overview
The TOGETHER-PsO Phase 3b trial evaluated the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) against Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight. Conducted over 36 weeks, the study aimed to assess the efficacy of this combination in achieving skin clearance and weight loss.
Key Findings
The trial met its primary endpoint, with 27.1% of participants on Taltz and Zepbound achieving complete skin clearance (PASI 100) and at least 10% weight loss, compared to 5.8% on Taltz alone. A key secondary endpoint showed a 40% relative increase in PASI 100 achievement for the combination therapy over Taltz monotherapy, with 40.6% of patients reaching this outcome versus 29.0% for Taltz alone.
Patient Demographics
The study involved patients with a high disease burden, characterized by an average BMI of over 39 kg/m², which is significantly higher than in previous psoriasis biologic trials. Most participants had extensive skin involvement, with about 25% body surface area affected, and nearly all had psoriasis in high-impact areas like the face, scalp, or genitals.
Adverse Events
Adverse events for the combination treatment were generally mild to moderate, aligning with known safety profiles. Common events included nausea, diarrhea, constipation, injection site reactions, and dizziness. In the Taltz monotherapy group, common events were injection site reactions, dosing errors, and nasopharyngitis.
